Jennerex Announces Presentations at Upcoming Conferences

    


    
</pre>
<p><location>SAN FRANCISCO</location>, <chron>Dec. 23</chron> /CNW/ -- Jennerex Biotherapeutics, a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced that management will present at the following upcoming investor conferences.</p>
<p/>
<p> </p>
<p> </p>
<pre>
    
    Biotech Showcase 2010
    Tuesday, January 12, 2010
    9:40 a.m. PT
    Marines' Memorial Club and Hotel, San Francisco
    
</pre>
<p> </p>
<pre>
    
    OneMedForum 2010
    Wednesday, January 13, 2010
    2:40 p.m. PT
    Sir Francis Drake Hotel, San Francisco


    About Jennerex
    
</pre>
<p>Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells. These products not only cause cancer cell lysis thereby killing through replication, they simultaneously shut-off the blood supply to tumors, as well as stimulating the body's immune response to the cancer. Jennerex, Inc. is headquartered in <location>San Francisco</location> and has manufacturing and research activities based at the <location>Ottawa</location> Hospital Research Institute in <location>Ottawa</location>, <location>Canada</location>. For more information about Jennerex and the Company's pipeline of three clinical-stage products, please visit <a href="http://www.jennerex.com">www.jennerex.com</a> .</p>
<pre>
    




    

For further information: Jennifer Cook Williams of Cook Williams Communications, Inc., [phone], [email protected], for Jennerex Biotherapeutics Web Site: http://www.jennerex.com